Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03524339 · ClinicalTrials.gov registry record · Phase 2
Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery
A Phase 2 study, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT03524339 is a Phase 2 study that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 132 participants.
The verdict
NCT03524339, a Phase 2 study, has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
This is a placebo controlled randomized controlled trial of perioperative use of tamsulosin to prevent postoperative urinary retention in female pelvic reconstructive surgery.
Interventions
- DRUG Placebo oral capsule
- DRUG Tamsulosin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2020-06-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03524339
The ClinicalTrials.gov registry entry for NCT03524339 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03524339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03524339 about?
NCT03524339 is a clinical study titled "Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery". This is a placebo controlled randomized controlled trial of perioperative use of tamsulosin to prevent postoperative urinary retention in female pelvic reconstructive surgery.
What is the current status of trial NCT03524339?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2018-08-01. Estimated completion is 2020-06-09.
What interventions are being tested in trial NCT03524339?
The interventions under investigation include: Placebo oral capsule (DRUG), Tamsulosin (DRUG).
Who is sponsoring clinical trial NCT03524339?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.